|
Market Closed -
London S.E.
11:35:02 2026-10-09 EDT
|
5-day change | 1st Jan Change | ||
| 40.40 GBX | -2.65% |
|
+9.19% | +13.96% |
| 09-08 | EARNINGS AND TRADING: Acuity eyes 'breakeven' as loss narrows | AN |
| 09-08 | Novacyt S.A. Launches IVDR-Certified Yourgene Insight DPYD Assay | CI |
Company Valuation: Novacyt
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 309.3 | 86.78 | 42.47 | 27.57 | 33.71 | - |
| Change | - | -71.94% | - | -35.08% | 22.28% | - |
| Enterprise Value (EV) 1 | 190.3 | 86.78 | 42.47 | 17.5 | 35.67 | 38.56 |
| Change | - | -54.41% | - | -58.79% | 103.82% | 8.09% |
| P/E | - | -3.01x | -0.87x | - | - | - |
| PBR | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - |
| Capitalization / Revenue | 2.72x | - | - | 1.19x | 1.1x | 0.97x |
| EV / Revenue | 1.67x | - | - | 0.75x | 1.17x | 1.11x |
| EV / EBITDA | 4.32x | - | - | -1.94x | -5.19x | -14.1x |
| EV / EBIT | 4.57x | - | - | -1.33x | -3.57x | -7.31x |
| EV / FCF | - | - | - | -1.59x | -3.98x | -8.9x |
| FCF Yield | - | - | - | -62.7% | -25.1% | -11.2% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | -0.408 | -0.6934 | - | - | - |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 113.8 | - | - | 23.18 | 30.52 | 34.86 |
| EBITDA 1 | 44.06 | - | - | -9.014 | -6.878 | -2.727 |
| EBIT 1 | 41.68 | - | - | -13.13 | -10 | -5.273 |
| Net income | - | -29.16 | -49.07 | - | - | - |
| Net Debt 1 | -119 | - | - | -10.07 | 1.956 | 4.842 |
| Reference price 2 | 4.3800 | 1.2295 | 0.6020 | 0.3910 | 0.4650 | 0.4650 |
| Nbr of stocks (in thousands) | 70,616 | 70,582 | 70,547 | 70,511 | 72,502 | - |
| Announcement Date | 4/28/22 | 4/27/23 | 4/30/25 | 4/30/26 | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.5x | 7.3x | 14.66x | 1.45% | 70.61B | |
| 27.46x | 7.51x | 23.56x | 0.05% | 51.01B | |
| 33.37x | 6x | 17.96x | 0.97% | 48.1B | |
| 33.47x | 3.25x | 14.03x | -.--% | 42.78B | |
| -19.64x | 203.45x | -20.92x | -.--% | 40.67B | |
| 46.95x | 5.34x | 29.33x | -.--% | 40.3B | |
| 27.18x | 7.73x | 20.09x | 0.42% | 30.59B | |
| 32.53x | 6.94x | 18.03x | -.--% | 28.16B | |
| -14.69x | 5.97x | -7.21x | -.--% | 24.36B | |
| Average | 20.79x | 28.17x | 12.17x | 0.32% | 41.84B | |
| Weighted average by Cap. | 22.22x | 27.60x | 13.22x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALNOV Stock
- NCYT Stock
- Valuation Novacyt
Select your edition
All financial news and data tailored to specific country editions
